Evidence map›Paper›PMID 31791397›Full record

ArticleStem cell research & therapy2019

Intervention for early diabetic nephropathy by mesenchymal stem cells in a preclinical nonhuman primate model.

Xingxing An, Guangneng Liao, Younan Chen, Ai Luo, Jingping Liu, Yujia Yuan, Lan Li, Lichuan Yang, Hong Wang, Fang Liu and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 3 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Molecular Therapeutics for Diabetic Kidney Disease: An Update.International journal of molecular sciences · 2024
    Review
  10. Review
  11. The therapeutic effect of mesenchymal stem cells in diabetic kidney disease.Journal of molecular medicine (Berlin, Germany) · 2024
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Xingxing AnKey Laboratory of Transplant Engineering and Immunology, NHFPC, West China Hospital, Sichuan University, Chengdu, China.
Guangneng LiaoAnimal Center, West China Hospital, Sichuan University, Chengdu, China.
Younan ChenKey Laboratory of Transplant Engineering and Immunology, NHFPC, West China Hospital, Sichuan University, Chengdu, China.
Ai LuoSichuan Neo-Life Stem Cell Biotech Inc., Chengdu, China.
Jingping LiuKey Laboratory of Transplant Engineering and Immunology, NHFPC, West China Hospital, Sichuan University, Chengdu, China.
Yujia YuanKey Laboratory of Transplant Engineering and Immunology, NHFPC, West China Hospital, Sichuan University, Chengdu, China.
Lan LiKey Laboratory of Transplant Engineering and Immunology, NHFPC, West China Hospital, Sichuan University, Chengdu, China.
Lichuan YangDepartment of Nephrology, West China Hospital, Sichuan University, Chengdu, China.
Hong WangDepartment of Ultrasound, West China Hospital, Sichuan University, Chengdu, China.
Fang LiuDepartment of Nephrology, West China Hospital, Sichuan University, Chengdu, China.
Guang YangAnimal Center, West China Hospital, Sichuan University, Chengdu, China.
Shounan YiCenter for Transplant and Renal Research, Westmead Institute for Medical Research, The University of Sydney, Camperdown, NSW, Australia.
Yuanmin LiKey Laboratory of Transplant Engineering and Immunology, NHFPC, West China Hospital, Sichuan University, Chengdu, China.
Jingqiu ChengKey Laboratory of Transplant Engineering and Immunology, NHFPC, West China Hospital, Sichuan University, Chengdu, China. jqcheng@scu.edu.cn.
Yanrong LuKey Laboratory of Transplant Engineering and Immunology, NHFPC, West China Hospital, Sichuan University, Chengdu, China. luyanrong@scu.edu.cn.
West China Hospital of Sichuan University · CNSichuan University · CNUniversity of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiabetic nephropathy (DN) is one of the most severe chronic diabetic complications and the main cause of end-stage renal disease. Chronic inflammation plays a key role in the development of DN. However, few treatment strategies are available; therefore, new and effective strategies to ameliorate DN at the early stage must be identified.

methodsMesenchymal stem cells (MSCs) are characterized by anti-inflammatory and immune regulatory abilities. We developed a rhesus macaque model of DN and administered MSCs four times over 2 months. We measured blood glucose level, HbA1c, and levels of renal function parameters in the blood and urine, and cytokine levels in the kidney and blood circulatory system of rhesus macaques. Also, we analyzed the renal pathological changes of rhesus macaques. In vitro, we treated tubular epithelial cells (HK2) with 30 mmol/L glucose and 10 ng/mL human recombinant TNF-alpha (rhTNF-α) and explored the effects of MSCs on inflammation and Na

resultsWe found that MSCs decreased the blood glucose level and daily insulin requirement of DN rhesus macaques. Furthermore, MSCs had a dominant function in improving renal function and decreasing SGLT2 expression on renal tubular epithelial cells. Also, renal pathological changes were ameliorated after MSC treatment. Moreover, MSCs powerfully reduced inflammation, especially decreased the level of pro-inflammatory cytokine interleukin-16 (IL-16), in the kidney and blood circulatory system.

conclusionsOur study is an important step to explore the mechanism of MSCs in ameliorating the early stage of DN, potentially through influencing SGLT2 expression and resulting in improved glycemic control and anti-inflammation. We hope these findings would provide insights for the clinical application of MSCs in DN.

Indexed as

Mesenchymal Stem Cell TransplantationAnimalsBlood GlucoseCytokinesDiabetes Mellitus, ExperimentalDiabetic NephropathiesDiet, High-FatDisease Models, AnimalGlycated HemoglobinHumansKidneyKidney Tubules, ProximalMacaca mulattaMaleMesenchymal Stem CellsProto-Oncogene Proteins c-bcl-2Blood GlucoseCytokinesGlycated Hemoglobinhemoglobin A1c protein, humanProto-Oncogene Proteins c-bcl-2Sodium-Glucose Transporter 2Diabetic nephropathyInflammationMesenchymal stem cellsNonhuman primate modelSGLT2 inhibition

Identifiers

PMID31791397
PMCPMC6889652
OpenAlexW2993667222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.